The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease

1 Departments of Pediatrics and Medicine, National Jewish Health, Denver, Colorado; and ; 2 Department of Pediatrics, Case Western Reserve University School of Medicine, Rainbow Babies and Children's Hospital, Cleveland, Ohio Submitted 28 May 2009 ; accepted in final form 14 August 2009 Excessi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of physiology. Lung cellular and molecular physiology 2009-11, Vol.297 (5), p.L828-L836
Hauptverfasser:	Nichols, David P, Ziady, Assem G, Shank, Samuel L, Eastman, Jean F, Davis, Pamela B
Format:	Artikel
Sprache:	eng
Schlagworte:	Airway management Animals Antioxidants - metabolism Bronchi - cytology Bronchoalveolar Lavage Cell Line Cell Proliferation - drug effects Cystic fibrosis Cystic Fibrosis - complications Cystic Fibrosis - prevention & control Cystic Fibrosis Transmembrane Conductance Regulator - antagonists & inhibitors Cystic Fibrosis Transmembrane Conductance Regulator - metabolism Disease Models, Animal Epithelial Cells - drug effects Epithelial Cells - metabolism Epithelial Cells - pathology Flagellin - administration & dosage Flagellin - pharmacology Humans Inflammation - complications Inflammation - prevention & control Inflammation Mediators - metabolism Inflammatory diseases Interleukin-8 - secretion Lipopolysaccharides - pharmacology Mice Mutation Neutrophils - cytology Neutrophils - drug effects NF-E2-Related Factor 2 - metabolism NF-kappa B - metabolism Oleanolic Acid - administration & dosage Oleanolic Acid - analogs & derivatives Oleanolic Acid - pharmacology Oxidation-Reduction - drug effects Proteomics Respiratory diseases Rodents Therapy Trachea - cytology Translational Physiology Triterpenes - administration & dosage Triterpenes - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!